Personalized Pain Management Using Genetics for Adults Undergoing Lumbar Spine Fusion and Decompression Surgery

What this Trial Is About

Researchers are studying how genetic factors influence the effects of two common oral opioids, oxycodone and methadone, in adults after lumbar spinal fusion and decompression surgery. This research aims to better understand how multiple genes together affect opioid processing, dosing, safety, and effectiveness, especially in patients undergoing these painful spine surgeries. The study builds on ongoing efforts to improve personalized pain management and reduce risks of opioid-related problems such as respiratory depression and chronic post-surgical pain. The study involves patients undergoing lumbar spine surgeries who will receive opioids for pain management. It evaluates genetic markers combined with clinical risk factors to predict opioid responses and adverse events. The research uses a personalized approach integrating polygenetic signatures to guide postoperative opioid use. Methadones effects will also be assessed when used alongside oxycodone in certain inpatient surgeries. This observational study does not assign treatments but monitors patients opioid use and outcomes. Participants will be followed from before surgery through up to 12 months after surgery. Researchers will collect data on opioid-related nausea, sedation, respiratory depression, pain scores, opioid use, length of hospital stay, chronic post-surgical pain, and risks of opioid dependence or disorder. Preoperative assessments include pain tests and brain imaging signals. The study aims to develop tools to help clinicians plan personalized pain management to reduce opioid side effects and improve pain relief after surgery.

OpalGenix- Personalized Postoperative Pain Management Following Lumbar Spinal Fusion and Decompression Surgery in Adults